EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2 . EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus ( LCMV ). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses.
Products | Products > Disease Areas > Infection | Products > Disease Areas > Hepatitis Virus Infection | Products > Disease Areas > Viral Infection | Products > Disease Areas > Hepatitis C Virus Infection | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > RSV | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > HCV
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.